^
    19h
    Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial. (PubMed, J Immunother Cancer)
    ALECSAT, in combination with carboplatin and gemcitabine, was safe, well tolerated, and demonstrated promising antitumor activity in mTNBC. These findings support further investigation in larger clinical trials.
    P1 data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)
    3d
    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov)
    P1, N=23, Terminated, Xencor, Inc. | N=128 --> 23 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    9d
    A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P1/2, N=33, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed | N=150 --> 33 | Trial completion date: Mar 2027 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date
    16d
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    21d
    A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (clinicaltrials.gov)
    P3, N=124, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    25d
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    1m
    ALLELE: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (clinicaltrials.gov)
    P3, N=115, Recruiting, Pierre Fabre Medicament | N=66 --> 115
    Enrollment change
    |
    Rituxan (rituximab) • Tab-cel (tabelecleucel)
    1m
    MARCH: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Vir Biotechnology, Inc. | Trial completion date: Jun 2027 --> Mar 2026 | Trial primary completion date: Jun 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    2ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Suspended, Dwight Owen | Recruiting --> Suspended
    Trial suspension
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    2ms
    ALLELE: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (clinicaltrials.gov)
    P3, N=66, Recruiting, Pierre Fabre Medicament | Trial primary completion date: Aug 2025 --> May 2030
    Trial primary completion date
    |
    Rituxan (rituximab) • Tab-cel (tabelecleucel)
    2ms
    MELODY-1: A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Microbiotica Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    2ms
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial primary completion date • Platinum resistant
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)